{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T16:38:04Z","timestamp":1722098284053},"reference-count":33,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,3,5]],"date-time":"2017-03-05T00:00:00Z","timestamp":1488672000000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:p>Ruxolitinib is a dual janus kinase 1 (<jats:styled-content style=\"fixed-case\">JAK1<\/jats:styled-content>)\/<jats:styled-content style=\"fixed-case\">JAK2<\/jats:styled-content> inhibitor used to treat splenomegaly and symptoms associated with myelofibrosis (<jats:styled-content style=\"fixed-case\">MF<\/jats:styled-content>). Current therapeutic options for symptomatic MF include supportive care, myelosuppressive therapy (such as hydroxycarbamide) and janus kinase (<jats:styled-content style=\"fixed-case\">JAK<\/jats:styled-content>) inhibitors (in particular ruxolitinib). Allogeneic stem cell transplantation remains the only potentially curative treatment for <jats:styled-content style=\"fixed-case\">MF<\/jats:styled-content>, and younger transplant\u2010eligible patients should still be considered for allogeneic stem cell transplantation; however, this is applicable only to a small proportion of patients. There is now increasing and extensive experience of the efficacy and safety of ruxolitinib in MF, both in clinical trials and in \u2018real\u2010world\u2019 practice. The drug has been shown to be of benefit in intermediate\u20101 risk patients with symptomatic splenomegaly or other <jats:styled-content style=\"fixed-case\">MF<\/jats:styled-content>\u2010related symptoms, and higher risk disease. Optimal use of the drug is required to maximise clinical benefit, requiring an understanding of the balance between dose\u2010dependent responses and dose\u2010limiting toxicities. There is also increasing experience in the use of ruxolitinib in the pre\u2010transplantation setting. This paper aims to utilise several \u2018real\u2010life\u2019 cases to illustrate several strategies that may help to optimise clinical practice.<\/jats:p>","DOI":"10.1111\/imj.13341","type":"journal-article","created":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T00:15:27Z","timestamp":1488759327000},"page":"262-268","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A case\u2010based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis"],"prefix":"10.1111","volume":"47","author":[{"given":"P. Joy","family":"Ho","sequence":"first","affiliation":[{"name":"Royal Prince Alfred Hospital, and  Sydney NSW Australia"},{"name":"University of Sydney, NSW  Sydney NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish","family":"Bajel","sequence":"additional","affiliation":[{"name":"The Royal Melbourne Hospital  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Burbury","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay","family":"Dunlop","sequence":"additional","affiliation":[{"name":"Liverpool Hospital  Sydney NSW Australia"},{"name":"Western Sydney University  Sydney NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Durrant","sequence":"additional","affiliation":[{"name":"Royal Brisbane Hospitals  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecily","family":"Forsyth","sequence":"additional","affiliation":[{"name":"Jarrett Street Specialist Centre  North Gosford NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew C.","family":"Perkins","sequence":"additional","affiliation":[{"name":"Princess Alexandra Hospital  Brisbane Queensland Australia"},{"name":"Wesley Hospital  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Ross","sequence":"additional","affiliation":[{"name":"SA Pathology, Royal Adelaide Hospital  Brisbane South Australia Australia"},{"name":"Flinders Medical Centre  Adelaide South Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,3,5]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-485888"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.115840"},{"key":"e_1_2_10_4_1","volume-title":"Long\u2010Term Outcomes of Ruxolitinib (rux) Therapy in Patients (pts) with Myelofibrosis (mf): 5\u2010Year Final Efficacy and Safety Analysis from COMFORT\u2010I","author":"Verstovsek S","year":"2016"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.148"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.12921"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.258"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-238956"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.03.042"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-482232"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.0057"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000446"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-6-79"},{"key":"e_1_2_10_16_1","volume-title":"Jakavi\u00ae (ruxolitinib) product information","author":"Novartis Pharmaceuticals Australia Pty Ltd","year":"2015"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-015-0021-2"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05229.x"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-531103"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-484642"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2007.04.007"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2011.0518"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1195501"},{"key":"e_1_2_10_24_1","volume-title":"P675 Safety and Efficacy of Ruxolitinib with Intermediate\u20101\u2010Risk Myelofibrosis from an Open\u2010Label, Multicenter, Single\u2010Arm Expanded Access Study","author":"Giraldo P","year":"2015"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13379"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.173"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.10.005"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.212"},{"key":"e_1_2_10_29_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.306.306","article-title":"Ruxolitinib before allogeneic hematopoietic stem cell transplantation (hsct) in patients with myelofibrosis: a preliminary descriptive report of the JAK ALLO Study, a phase II trial sponsored by Goelams\u2010FIM in collaboration with the Sfgmtc","volume":"122","author":"Robin M","year":"2013","journal-title":"Blood"},{"key":"e_1_2_10_30_1","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/blood.V122.21.392.392","article-title":"Ruxolitnib as pretreatment before allogeneic stem cell transplantation for myelofibrosis","volume":"122","author":"Kroger N","year":"2013","journal-title":"Blood"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0041-2015"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.5"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.120816"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.01.001"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fimj.13341","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.13341","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T22:54:34Z","timestamp":1695509674000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.13341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1111\/imj.13341"],"URL":"https:\/\/doi.org\/10.1111\/imj.13341","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"2016-11-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-11-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-03-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}